Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

It was a presentation at the American Society of Hematology (ASH) conference that swayed Jazz Pharmaceuticals to put up $15 million upfront to join Werewolf Therapeutics on the prowl. The backloaded ...

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other ...

Werewolf Therapeutics, Inc. (HOWL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HOWL's 50-day simple moving average ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

MPM Asset Management LLC and related entities, all of whom are 10% owners of Werewolf Therapeutics, Inc. (NASDAQ:HOWL), sold a total of 179551 shares of common stock for approximately $179,551. The ...

A few weeks back you might recall that we gave you the first heads up on a new werewolf film on the horizon called Howl (“Fever Pitch Ready to Howl” – November 2007). Since that story went up, ...